Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells

Cong Peng, Julia Brain, Yiguo Hu, Ami Goodrich, Linghong Kong, David Grayzel, Roger Pak, Margaret Read, Shaoguang Li

Blood (2007) 110 (2): 678–685.

https://doi.org/10.1182/blood-2006-10-054098

Published: 2007

Journal Articles

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

David Siegel, MD, PhD, Sundar Jagannath, MD, Amitabha Mazumder, MD, David Vesole, MD, Ivan Borrello, MD, Jens Sydor, PhD, Jim Wright, PhD, Jon Patterson, BS, Emmanuel Normant, PhD, Julian Adams, PhD, Kenneth Anderson, MD, David Grayzel, MD, Paul Richardson, MD

Blood (2006) 108 (11): 3579.

https://doi.org/10.1182/blood.V108.11.3579.3579

Published: 2006

Journal Articles

IPI-504, a Novel, Orally Active HSP90 Inhibitor, Prolongs Survival of Mice with BCR-ABL T315I CML and B-ALL.

Cong Peng, MS, Julia Brain, PhD, Yiguo Hu, MD, Linghong Kong, MD, PhD, David Grayzel, MD, Roger Pak, PhD, Margaret Read, PhD, Shaoguang Li, MD, PhD

Blood (2006) 108 (11): 2183.

https://doi.org/10.1182/blood.V108.11.2183.2183

Published: 2006

Journal Articles

Hsp-90 Inhibition Decreases Survival of BCR-ABL T315I Leukemic Stem Cells in Mice.

Cong Peng, MS, Julia Brain, PhD, Yiguo Hu, MD, Linghong Kong, MD, PhD, Ami Goodrich, David Grayzel, MD, Roger Pak, PhD, Margaret Read, PhD, Shaoguang Li, MD, PhD

Blood (2006) 108 (11): 2184.

https://doi.org/10.1182/blood.V108.11.2184.2184

Published: 2006

Journal Articles

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Sundar Jagannath, MD, David Siegel, MD, Paul Richardson, MD, Amitabha Mazumder, MD, Jens Sydor, PhD, Jill Goddard, John Walker, Jon Patterson, Emmanuel Normant, PhD, Jeffrey Tong, PhD, Vito Palombella, PhD, Ken Anderson, MD, Julian Adams, PhD, David Grayzel, MD

Blood (2005) 106 (11): 2560.

https://doi.org/10.1182/blood.V106.11.2560.2560

Published: 2005

Journal Articles

Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma.

Blood (2004) 104 (11): 4922.

https://doi.org/10.1182/blood.V104.11.4922.4922

Published: 2004

Journal Articles

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Joseph Negri, Corey C. Geer, MSc, Melissa Pink, Christine Pien, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Paul G. Richardson, MD, John Barrett, PhD, Jeffrey K. Tong, PhD, David Grayzel, Vito Palombella, PhD, Julian Adams, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2403.

https://doi.org/10.1182/blood.V104.11.2403.2403

Published: 2004

NARROW

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

IPI-504, a Novel, Orally Active HSP90 Inhibitor, Prolongs Survival of Mice with BCR-ABL T315I CML and B-ALL.

Hsp-90 Inhibition Decreases Survival of BCR-ABL T315I Leukemic Stem Cells in Mice.

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma.

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Email alerts

ASH Publications

American Society of Hematology

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells

Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

IPI-504, a Novel, Orally Active HSP90 Inhibitor, Prolongs Survival of Mice with BCR-ABL T315I CML and B-ALL.

Hsp-90 Inhibition Decreases Survival of BCR-ABL T315I Leukemic Stem Cells in Mice.

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma.

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only